About: Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 October 2005

AttributesValues
rdf:type
description
  • wetenschappelijk artikel (nl)
  • article scientifique publié en 2005 (fr)
  • наукова стаття, опублікована в жовтні 2005 (uk)
  • im Oktober 2005 veröffentlichter wissenschaftlicher Artikel (de)
  • artículu científicu espublizáu n'ochobre de 2005 (ast)
  • scientific article published on 01 October 2005 (en)
publication date
publication date
exact match
exact match
cites work
cites work
author name string
author name string
  • Z Berneman
  • F Mandelli
  • R Willemze
  • P Muus
  • T de Witte
  • S Suciu
  • J-P Marie
  • V Cassibba
  • R Stauder
  • D Selleslag
  • R Stasi
  • F Nobile
  • C Denzlinger
  • F Beeldens
  • J Pruijt
  • L Baila
rdfs:label
  • Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup (en)
  • Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup (nl)
skos:prefLabel
  • Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup (en)
  • Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup (nl)
name
  • Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup (en)
  • Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup (nl)
author
author
title
title
  • Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups (en)
page(s)
page(s)
  • 1768-1773
instance of
instance of
main subject
main subject
PubMed ID
PubMed ID
PubMed ID
  • 16079891
published in
published in
issue
volume
issue
  • 10
volume
  • 19
DOI
DOI
DOI
  • 10.1038/SJ.LEU.2403901
Dimensions Publication ID
Faceted Search & Find service v1.16.117 as of May 05 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software